In the FIND trial, Non Small Cell Lung Carcinoma (NSCLC) patients with Fibroblast Growth
Factor Receptor (FGFR) genetic alteration will be treated with the selective FGFR1-4
inhibitor erdafitinib. Archival samples, fresh frozen tumor samples and blood for circulating
tumor DNA (ctDNA) will be collected before treatment. Patients will be treated until disease
progression or unacceptable toxicity. In case of progression, fresh frozen tumor biopsies and
ctDNA analyses will be performed to assess resistance mechanisms. The primary objective of
the trial is to analyze the efficacy of erdafitinib in NSCLC patients with FGFR genetic
alterations. NSCLC patient number will be based on a statistical hypothesis aiming at
increasing the response rate comparing to chemotherapy/immunotherapy after standard
treatment.